<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04416282</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-ACLF-04</org_study_id>
    <nct_id>NCT04416282</nct_id>
  </id_info>
  <brief_title>Efficacy of Early Terlipressin Plus Albumin Therapy in Comparison to Standard Treatment for HRS-AKI in Acute-on-chronic Liver Failure.</brief_title>
  <official_title>Efficacy of Early Terlipressin Plus Albumin Therapy in Comparison to Standard Treatment for HRS-AKI in Acute-on-chronic Liver Failure- A Randomized Open Label Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute on chronic liver failure (ACLF) is a distinct entity where, because of severe acute&#xD;
      hepatic injury, a rapid loss of liver function develops in a patient with previous chronic&#xD;
      liver disease(4). These patients have severe hepatic dysfunction, and outcome is defined by&#xD;
      functional hepatic reserve and extent of extra-hepatic organ failures(5). Renal failure is a&#xD;
      frequent extra-hepatic organ failure, and its presence is an independent prognostic marker&#xD;
      for mortality(12). The pathophysiological basis of renal dysfunction in patients with ACLF is&#xD;
      different compared to those with decompensated cirrhosis (DC)(6). Systemic inflammation is&#xD;
      the hallmark of ACLF, characterized by a cytokine storm wherein there is an increase in both&#xD;
      pro- and anti-inflammatory cytokines, such as interleukin (IL)-6, IL-8, IL-1Î², and IL-10,&#xD;
      leading to circulatory dysfunction and organ failure(3). These patients therefore have a&#xD;
      higher incidence and progression of acute kidney injury (AKI). Diagnosis of HRS-AKI in ACLF&#xD;
      currently requires 48 h of volume repletion with albumin and diuretic withdrawal. Therefore&#xD;
      waiting for 48 hours to start treatment with terlipressin can be associated with worsening of&#xD;
      AKI stage, worsening of ACLF stage and thereby suboptimal treatment response and high&#xD;
      mortality despite treatment response. Therefore early initiation of terlipressin as&#xD;
      continuous infusion after volume repletion with IV albumin in ACLF-AKI is safe and prevents&#xD;
      AKI progression by splanchnic vasoconstriction and improved renal perfusion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim To compare the effect of Early initiation of Terlipressin (ET arm) to albumin at 12 hour&#xD;
      in ACLF patients with non-volume responsive AKI versus standard Terlipressin (ST arm) at 48&#xD;
      hours.&#xD;
&#xD;
      Primary Objective Efficacy of early terlipressin infusion in comparison to Standard treatment&#xD;
      for resolution of AKI at day 7.&#xD;
&#xD;
      Secondary Objectives&#xD;
&#xD;
        -  Full and partial AKI response at 48 and 72 h and 96 hours&#xD;
&#xD;
        -  Mortality at Day 28, Day 90&#xD;
&#xD;
        -  Baseline organ failure(s), MELD, CLIF-SOFA score and ACLF score&#xD;
&#xD;
        -  New onset organ failures&#xD;
&#xD;
        -  Urine Output&#xD;
&#xD;
        -  Progression or resolution of OFs at day 7&#xD;
&#xD;
        -  Change in MELD, CLIF-SOFA score and ACLF score at day 7&#xD;
&#xD;
        -  Change in NGAL, FENa, FE-Urea at day 7&#xD;
&#xD;
        -  Treatment related adverse effects and their grades&#xD;
&#xD;
      Methodology:&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      All patients admitted to the Institute of Liver and Biliary Sciences (ILBS) with ACLF with&#xD;
      AKI- HRS will be evaluated for inclusion. ACLF will be defined by the APASL criteria.&#xD;
&#xD;
      Study Design A prospective, randomized, single center open label study&#xD;
&#xD;
      Study Period:Two year&#xD;
&#xD;
      Intervention &amp; monitoring:&#xD;
&#xD;
      Clinical Protocol An informed consent will be taken from ACLF patients with AKI within&#xD;
      24-hours of admission. No alteration in the treatment or investigative procedures of the&#xD;
      included patients will be done. All included patients will be followed from admission till&#xD;
      death or discharge. All discharged patients will then be followed till 30-days.&#xD;
&#xD;
      Preliminary work up&#xD;
&#xD;
      At admission:&#xD;
&#xD;
      (A) Complete history and physical examination&#xD;
&#xD;
        -  Recent Diuretics use&#xD;
&#xD;
        -  Loose stools&#xD;
&#xD;
        -  Recurrent vomiting&#xD;
&#xD;
        -  Fever, signs of sepsis (SIRS)&#xD;
&#xD;
        -  H/s/o LRTI, SSTI, SBP&#xD;
&#xD;
        -  Recent contrast use (&lt; 7 days)&#xD;
&#xD;
        -  Use of nephrotoxins including NSAIDs&#xD;
&#xD;
        -  Prior renal dysfunction, known CKD, HD&#xD;
&#xD;
        -  History of HTN, Diabetes&#xD;
&#xD;
        -  History of renal stones&#xD;
&#xD;
        -  History s/o hypotensive episodes (shock)&#xD;
&#xD;
      Pre-randomization interventions:&#xD;
&#xD;
      (B) Intervention during 0-12 hours (Before randomization) -&#xD;
&#xD;
        -  Withdrawal of diuretics&#xD;
&#xD;
        -  Withdrawal of lactulose (in patients with loose stools)&#xD;
&#xD;
        -  Urine output monitoring (catheterize and monitor hourly or 12 h cumulative)&#xD;
&#xD;
        -  2 hourly MAP, Pulse rate&#xD;
&#xD;
        -  Empirical IV antibiotics to be given in case of suspected/proven sepsis (Avoid&#xD;
           nephrotoxic drugs e.g Amikacin, Colistin, Amphotericin etc as possible)&#xD;
&#xD;
        -  IV hydration with albumin at 12 hours preferably 40 g (20 %) + 500 ml crystalloids)&#xD;
&#xD;
      Labs and follow-up:&#xD;
&#xD;
        -  Baseline (at admission) - Blood : KFT, LFT, CBC, INR, Blood c/s, pro-BNP Imaging : USG&#xD;
           abdomen, USG KUB, Renal doppler, C-X-ray, 2D ECHO Urine : Urine R/E and cultures, Urine&#xD;
           Na, Urea, NGAL, Creatinine, FENa, FE Urea A/F analysis - for SBP&#xD;
&#xD;
        -  At 12 hours (Before randomization) - Blood - KFT&#xD;
&#xD;
        -  At D1, D2, D3, D5, D7, D14, D28 post randomization Blood : KFT Urine : Urine Na, Urea,&#xD;
           NGAL, Creatinine, FENa, FE Urea (At Day 3 and 7) Imaging : Renal doppler (Day 3)&#xD;
&#xD;
      Clinical evaluation:&#xD;
&#xD;
        -  Etiology of cirrhosis (Baseline)&#xD;
&#xD;
        -  Severity of liver disease (Baseline, D3, D7) MELD score, CLIF-SOFA score, MELD-Na score,&#xD;
           AARC score&#xD;
&#xD;
        -  Stage of ACLF (Baseline,D3, D7) AARC grade, CLIF ACLF grade&#xD;
&#xD;
        -  Complications / Organ failures (Baseline,D3, D7) HE, Bleed, AKI stage, SBP, Infection&#xD;
           (specify site and severity) Respiratory and circulatory failure&#xD;
&#xD;
      Follow up duration Duration of admission till discharge or death will be noted. Patients will&#xD;
      be followed up to 28-days for re-admission(s) and survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2020</start_date>
  <completion_date type="Anticipated">June 10, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 10, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Kidney Injury reversal by day 7 in both groups</measure>
    <time_frame>Day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality in both groups</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality in both groups</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression or resolution of Organ failures</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events in both groups</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Acute-On-Chronic Liver Failure</condition>
  <condition>Hepatorenal Syndrome</condition>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Terlipressin + Albumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection terlipressin 2 mg/24 hours infusion + i/v albumin 1g/Kg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Albumin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>i/v albumin 1g/Kg/day for next 36 hours f/b inj terlipressin 2mg/24 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terlipressin</intervention_name>
    <description>Injection terlipressin 2 mg/24 hours infusion</description>
    <arm_group_label>Terlipressin + Albumin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Albumin</intervention_name>
    <description>i/v albumin 1g/Kg/day</description>
    <arm_group_label>Albumin</arm_group_label>
    <arm_group_label>Terlipressin + Albumin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-65 years&#xD;
&#xD;
          2. ACLF as per APASL criteria&#xD;
&#xD;
          3. AKI at admission as defined by ICA-AKI criteria&#xD;
&#xD;
          4. AKI stage 2/3 at 12 hour of admission&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
&#xD;
        At Admission:&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Patients on renal replacement therapy (RRT)&#xD;
&#xD;
          -  Post renal or liver transplantation&#xD;
&#xD;
          -  History of CAD, ischemic cardiomyopathy, PVD, ventricular arrhythmia&#xD;
&#xD;
          -  Decompensated cirrhosis not fulfilling ACLF criteria&#xD;
&#xD;
          -  Cirrhotics with AKI managed as outpatients&#xD;
&#xD;
          -  Grade III/IV HE or Shock requiring inotropes or patients on mechanical ventilator at&#xD;
             time of randomization&#xD;
&#xD;
          -  In-hospital new AKI&#xD;
&#xD;
          -  Active urinary sediments - 2+ albumin or above, dysmorphic RBCs&#xD;
&#xD;
          -  Known CKD, obstructive uropathy&#xD;
&#xD;
          -  Lack of informed consent&#xD;
&#xD;
          -  Prior intolerance or S/E to Terlipressin or albumin&#xD;
&#xD;
        At 12 Hour before randomization:&#xD;
&#xD;
        â¢ Regression of AKI (&gt;0.3 mg/dl) above baseline after IV albumin (20% 40 gm) + IV&#xD;
        Crystalloids 500 ml therapy for 12 hours&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr Hitesh Singh, MD</last_name>
    <phone>01146300000</phone>
    <email>hiteshrims04@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Liver &amp; Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Hitesh Singh, MD</last_name>
      <phone>01146300000</phone>
      <email>hiteshrims04@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 1, 2020</study_first_submitted>
  <study_first_submitted_qc>June 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2020</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
    <mesh_term>Hepatorenal Syndrome</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terlipressin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

